Current Strategy to Treat Immunogenic Gastrointestinal Cancers: Perspectives for a New Era

Since pembrolizumab, an anti-programmed death-1 (PD-1) antibody, showed a dramatic response to immunogenic cancers with microsatellite instability-high (MSI-H) and/or deficient mismatch repair (dMMR) in the pilot clinical trial KEYNOTE-016, subsequent studies have confirmed durable responses of anti...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimozaki, Keitaro, Nakayama, Izuma, Hirota, Toru, Yamaguchi, Kensei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10093684/
https://www.ncbi.nlm.nih.gov/pubmed/37048122
http://dx.doi.org/10.3390/cells12071049

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10093684/
https://www.ncbi.nlm.nih.gov/pubmed/37048122
http://dx.doi.org/10.3390/cells12071049

Ejemplares similares